1673-422X
2016 Issue 9
Study of transferrin modified doxorubicin liposome targeted to inhibit proliferation of breast cancer cells
Fan Hua;,Liu Minli;,Chang Qi;,Liu Yongfeng;,Sun Xuejun;,Zhang Shengjun;
Fan Hua;,Liu Minli;,Chang Qi;,Liu Yongfeng;,Sun Xuejun;,Zhang Shengjun;
..............page:641-645
Construction of colonic cancer drug-resistant cell line COLO and its relationship with tumor stem cells
Gan Yaping;,Guo Xiaohua;,Zhang Junyu;,Xu Qingqing;,Wu Jiang;,Wang Renyong;,Qiu Min;,Jiang Ru-gang;,Liu Fuxing;,Ning Zhifeng;
Gan Yaping;,Guo Xiaohua;,Zhang Junyu;,Xu Qingqing;,Wu Jiang;,Wang Renyong;,Qiu Min;,Jiang Ru-gang;,Liu Fuxing;,Ning Zhifeng;
..............page:646-650
Relationships between androgen receptor expression and clinicopathological features and prognosis of early-onset breast cancer in Xinjiang
Li Junting;,Zhang Yinhua;,Zhao Feng;
Li Junting;,Zhang Yinhua;,Zhao Feng;
..............page:651-654
Expression and significance of MET gene in non-small cell lung cancer
Wang Bo;,Wang Hui;,Qi Kang;,Zhang Lianbin;
Wang Bo;,Wang Hui;,Qi Kang;,Zhang Lianbin;
..............page:655-658
Comparison of clinical efficacy of gefitinib and erlotinib treating non-small-cell lung cancer with epider-mal growth factor receptor mutation in either exon 19 or 21
Shen Jie;,Li Yirong;,Gao Yuan;,Gao Hui;,Bai Lu;
Shen Jie;,Li Yirong;,Gao Yuan;,Gao Hui;,Bai Lu;
..............page:659-663
Expressions and clinicopathological significances of BMI-1 and PADI4 in esophageal squamous cell car-cinoma
Ji Huaijun;,Liu Peng;,Zhen Tianchang;,Su Gongzhang;,Sun Ningbo;,Jiang Zhongmin;
Ji Huaijun;,Liu Peng;,Zhen Tianchang;,Su Gongzhang;,Sun Ningbo;,Jiang Zhongmin;
..............page:664-668
Clinical observation of raltitrexed combined with irinotecan as first-line chemotherapy for recurrent or metastatic gastric cancer
Zhang Min;,Lu Weidong;,Xu Zhen;,Wang Shaokai;,Zuo Yun;
Zhang Min;,Lu Weidong;,Xu Zhen;,Wang Shaokai;,Zuo Yun;
..............page:669-672
Expression and role of SPARCL1 gene in tumor
Zhao Shujie;,Zhou Dong;
Zhao Shujie;,Zhou Dong;
..............page:673-675
Relationship among pyroptosis,inflammasome and tumor
Wang Jingxia;,Guo Xiaodong;
Wang Jingxia;,Guo Xiaodong;
..............page:676-680
Roles of microRNAs in the anti-tumor effects of metformin
Yang Libo;,Lyu Xiaohong;,Wu Shun;,Yue Feng;,Zhang Tie;
Yang Libo;,Lyu Xiaohong;,Wu Shun;,Yue Feng;,Zhang Tie;
..............page:681-683
Neoplasms chemosensitization enhancing effects of nitric oxide donor compounds
Zhang Caixia;,Liu Yangyun;
Zhang Caixia;,Liu Yangyun;
..............page:684-687
Behavior of cancers evolution
Zhang Baihong;,Yue Hongyun;
Zhang Baihong;,Yue Hongyun;
..............page:688-690
Models and mechanisms of collective cell migration in cancer
Xue Tongchun;,Ye Shenglong;
Xue Tongchun;,Ye Shenglong;
..............page:691-694
Research in thyroid carcinoma related factors
Yuan Sijie;,Long Jianhong;
Yuan Sijie;,Long Jianhong;
..............page:695-698
The correlation of PIK3CA gene mutation and the efficacy of anti-HER2 targeted therapy for breast cancer
Shao Xiying;,Zheng Yabing;,Wang Xiaojia;
Shao Xiying;,Zheng Yabing;,Wang Xiaojia;
..............page:699-702
Relationship between abnormal activation of HGF/c-Met signaling pathway and EGFR-TKI acquired resistance in non-small cell lung cancer
Nie Lin;,Xu Yuqing;
Nie Lin;,Xu Yuqing;
..............page:703-705
Long non-coding RNA in digestive system tumors
Pan Lei;,Liang Wei;,Fu Min;,Qian Hui;,Xu Wen-rong;,Jiang Pengcheng;,Zhang Xu;
Pan Lei;,Liang Wei;,Fu Min;,Qian Hui;,Xu Wen-rong;,Jiang Pengcheng;,Zhang Xu;
..............page:706-710
Research progress of thalidomide in usual non-hematologic malignancies
Lei Lei;,Wang Xian;,Wang Xiaojia;
Lei Lei;,Wang Xian;,Wang Xiaojia;
..............page:711-714
Changes of bone marrow microenvironment of myelodysplastic syndromes
Shen Na;,Li Qing;,Cheng Fanjun;
Shen Na;,Li Qing;,Cheng Fanjun;
..............page:715-717
bu tong fang liao fang shi dui zhong qi wei ai he bing gan ying hua men jing mai gao ya zheng huan zhe shu hou liao xiao de ying xiang
yang wen yan ;, ma tong sheng ;, zhi zuo ;, cao bo ;
yang wen yan ;, ma tong sheng ;, zhi zuo ;, cao bo ;
..............page:718-720